SLN
Silence Therapeutics plcNASDAQHealthcare$5.94-2.36%ClosedMarket Cap: $280.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.40
P/S
490.08
EV/EBITDA
-3.13
DCF Value
$0.42
FCF Yield
-22.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.5%
Operating Margin
-16292.8%
Net Margin
-15851.9%
ROE
-300.9%
ROA
-67.4%
ROIC
-77.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $34.0K | 64.7% | $-11.1M | $-11.8M | $-0.27 | — |
| FY 2025 | $559.0K | 61.5% | $-89.8M | $-88.6M | $-1.89 | — |
| Q3 2025 | $159.0K | 59.7% | $-26.2M | $-21.0M | $-1.32 | — |
| Q2 2025 | $224.0K | 62.1% | $-24.0M | $-27.4M | $-1.74 | — |
| Q1 2025 | $142.0K | 62.0% | $-28.4M | $-28.5M | $-1.80 | — |
| Q4 2024 | $24.3M | 93.4% | $-3.1M | $14.2M | $0.90 | — |
| FY 2024 | $43.3M | 72.7% | $-63.3M | $-45.3M | $-2.37 | — |
| Q3 2024 | $1.1M | -142.9% | $-22.5M | $-27.0M | $-1.71 | — |
| Q2 2024 | $598.0K | -341.1% | $-18.3M | $-15.6M | $-0.99 | — |
| Q1 2024 | $15.7M | 82.2% | $-5.6M | $-2.3M | $-0.16 | — |
| Q4 2023 | $2.1M | 35.9% | $-13.3M | $-14.4M | $-1.08 | — |
| FY 2023 | $25.4M | 59.3% | $-49.6M | $-43.3M | $-3.48 | — |